Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure

Circulation

Volumn 92, Issue 6, 1995, Pages 1479-1486

  Ferrari, Roberto ^a   Bachetti, Tiziana ^b   Confortini, Roberta ^a   Opasich, Cristina ^c   Febo, Oreste ^c   Corti, Angelo ^d   Cassani, Giovanni ^d   Visioli, Odoardo ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b Ctro Fisiopatol Cardiovascolare S   (Italy)

^c Clinica del Lavoro Foundation   (Italy)

^d Tecnogen SCpA   (Italy)

Author keywords

heart failure; hormones; proteins; receptors

Indexed keywords

ATRIAL NATRIURETIC FACTOR; CYTOKINE; NORADRENALIN; RECEPTOR PROTEIN; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ANTIGENICITY; ARTICLE; CACHEXIA; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; HUMAN; MALE; MUSCLE ATROPHY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DOMAIN; RECEPTOR DENSITY;

EID: 0029117828     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.92.6.1479     Document Type: Article

References (29)

1. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 1990;323:236-241.
2. McMurray J, Abdullah I, Dargie HJ, Shapiro D. Increased concentrations of tumor necrosis factor in 'cachectic' patients with severe chronic heart failure. Br Heart J. 1991;66:356-358.
3. Dutka DP, Elborn JS, Delamere F, Shale DJ, Morris GK. Tumor necrosis factor α in severe congestive cardiac failure. Br Heart J. 1993;70:141-143.
4. Katz SD, Rao R, Berman JW, Schwarz M, Demopoulos L, Bijou R, LeJemtel TH. Pathophysiological correlates of increased serum tumor necrosis factor in patients with congestive heart failure: relation to nitric oxide-dependent vasodilation in the forearm circulation. Circulation. 1994;90:12-16.
5. Sindhwani R, Yuen J, Hirsch H, Tedguy A, Galvao M, Levato P, LeJemtel TH. Reversal of low flow state attenuates immune activation in severely decompensated congestive heart failure. Circulation. 1993;88(pt 2):I-255. Abstract.
6. Ruff MR, Gifford GE. Purification and physico-chemical characterization of rabbit tumor necrosis factor. J Immunol. 1980;125: 1671-1677.
7. Mosmann T. Rapid colorimctric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65:55-63.
8. Tartaglia LA, Goeddel DV. Two TNF receptors. Immunol Today. 1992;13:151-153.
9. Smith CA, Farrah T, Goodwin RG. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell. 1994;76:959-962.
10. Engelmann H, Aderka D, Rubinstein M, Rotman D, Wallach D. A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. J Biol Chem. 1989;264:11974-11980.
11. Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med. 1992;175:323-329.
12. De Groote D, Grau GE, Dehart I, Franchimont P. Stabilization of functional tumor necrosis factor-α by its soluble TNF receptors. Eur Cytokine Netw. 1993;4:359-362.
13. Anand IS, Ferrari R, Kalra GS, Wahi PL, Poole-Wilson PA, Harris P. Edema of cardiac origin: studies of body water and sodium, renal function, hemodynamic indexes, and plasma hormones in untreated congestive cardiac failure. Circulation. 1989;80:299-305.
14. Ceconi C, Condorelli E, Quinzanini M, Rodella A, Ferrari R, Harris P. Noradrenaline, atrial natriuretic peptide, bombesin and neurotensin in myocardium and blood of rats in congestive cardiac failure. Cardiovasc Res. 1989;23:674-682.
15. Ferrari R, Anand IS, Kalra GS, Wahi PL, Poole-Wilson PA, Harris P. Body fluid compartments, renal function, hormone levels and hemodynamics in untreated congestive heart failure. Circulation. 1988;28:106. Abstract.
16. Poiesi C, Rodella A, Mantero G, Cannella G, Ferrari R, Albertini A. Improved radioimmunoassay of atrial natriuretic peptide in plasma. Clin Chem. 1989;35:1431-1434.
17. Nargi FE, Yang TJ. Optimization of the L-M cell bioassay for quantitating tumor necrosis factor α in serum and plasma. J Immunol Methods. 1993;159:81-91.
18. Corti A, Bagnasco L, Cassani G. Identification of an epitope of tumor necrosis factor (TNF)-receptor type I (P55) recognized by a TNF-α antagonist monoclonal antibody. Lymphokine Cytokine Res. 1994;13:183-190.
19. Ansari A. Syndromes of cardiac cachexia and the cachectic heart: current perspective. Prog Cardiovasc Dis. 1987;30:45-60.
20. Morrison WL, Edwards RHT. Cardiac cachexia. BMJ. 1991;302: 301-302.
21. Vassalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol 1992;10:411-452.
22. van Deuren M, Dofferhoff ASM, van der Meer JWM. Cytokines and the response to infection. J Pathol. 1992;168:349-356.
23. Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC, Lowry SF, Cerami A. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature. 1987;330: 662-664.
24. Mohler KM, Torrance DS, Smith CA, Goodwin RG, Stremler KE, Fung VP, Madani H, Widmer MB. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol. 1993;151:1548-1561.
25. Gruss HJ, Dolken G, Brach MA, Mertelsmann R, Herrmann F. The significance of serum levels of soluble 60kDa receptors for tumor necrosis factor in patients with Hodgkin's disease. Leukemia. 1993;7:1339-1343.
26. Aderka D, Wysenbeek A, Engelmann H, Cope AP, Brennan F, Molad Y, Hornik V, Levo Y, Maini RN, Feldmann M, Wallach D. Correlation between serum levels of soluble tumor necrosis factor receptors and disease activity in systemic lupus erythematosus. Arthritis Rheum. 1993;36:1111-1120.
27. Barrera P, Boerbooms AM, Janssen EM, Sauerwein RW, Gallati H. Mulder J, de Boo T, Demacker PN, van de Putte LB, van der Meer JW. Circulating soluble tumor necrosis factor receptors, interleukin-2 receptors, tumor necrosis factor alpha, and interleukin-6 levels in rheumatoid arthritis: longitudinal evaluation during methotrexate and azathioprine therapy. Arthritis Rheum. 1993;36:1070-1079.
28. Aukrust P, Liabakk NB, Muller F, Lien E, Espevik T, Froland SS. Serum levels of tumor necrosis factor-alpha (TNF-alpha) and soluble TNF receptors in human immunodeficiency virus type 1 infection: correlations to clinical, immunologic, and virologic parameters. J Infect Dis. 1994;169:420-424.
29. Zangerle R, Gallati H, Sarcletti M, Weiss G, Denz H, Wachter H, Fuchs D. Increased serum concentrations of soluble tumor necrosis factor receptors in HIV-infected individuals are associated with immune activation. J Acquir Immune Defic Syndr. 1994;7:79-85.